<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913507</url>
  </required_header>
  <id_info>
    <org_study_id>2018/14JUI/253</org_study_id>
    <nct_id>NCT03913507</nct_id>
  </id_info>
  <brief_title>Efficacy of a New Sweat Collection Support: Impact on Neonatal Screening and Early Treatment of Cystic Fibrosis</brief_title>
  <acronym>MACRODUCT-3710</acronym>
  <official_title>Efficacy of a New Sweat Collection Support: Impact on Neonatal Screening and Early Treatment of Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In nearly 25% of children under 3 months, the sweat test produces a quantity of sweat that&#xD;
      does not meet international recommendations and is insufficient to allow reliable and&#xD;
      reproducible biological analyzes in the sweat collected. In children between 3 and 12 months,&#xD;
      this rate is about 10% when it should not exceed 5%. Insufficient amount of sweat prevents&#xD;
      confirmation or reversal of the early diagnosis of cystic fibrosis and early treatment before&#xD;
      irreversible complications of the disease.&#xD;
&#xD;
      In this trial, a new support of sweat collection (Macroduct® Advanced Model 3710 Sweat&#xD;
      Collection System, Wescor) will be tested with the goal to increase the amount of sweat&#xD;
      collected during the sweat test, in comparison with the clinical routine method.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 14, 2018</start_date>
  <completion_date type="Actual">March 22, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>chloride concentration</measure>
    <time_frame>day 1</time_frame>
    <description>The volume and the chloride concentration will be analyzed for each subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sweat</measure>
    <time_frame>day 1</time_frame>
    <description>sweat collected with sweat collection method (Macroduct® Advanced) Model 3710 SYS, Wescor) compared with that currently used in clinical routine.&#xD;
The effectiveness criterion of the new Macroduct Advanced collector will be defined as follows: the new device tested will be considered effective if the insufficient amount of sweat levels obtained are smaller or equal to those recommended, i.e. if it is lower than 10% in children under 3 months and below 5% in children between 3 and 12 months.&#xD;
The insufficient amount of sweat rates will be compared between the two methods.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>one group : patients with suspicion of cystic fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Macroduct® Advanced Model 3710 SYS, Wescor</intervention_name>
    <description>for each subject, both methods will be tested in order to compare the efficacy of the new sweat collection method (Macroduct® Advanced Model 3710 SYS, Wescor) to the method currently used in clinical routine.</description>
    <arm_group_label>one group : patients with suspicion of cystic fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject aged of 2 days to 12 months&#xD;
&#xD;
          -  Indication of a sweat test prescribed by a clinician in a context of neonatal&#xD;
             screening&#xD;
&#xD;
          -  Clinically stable&#xD;
&#xD;
          -  Well hydrated&#xD;
&#xD;
          -  Not under treatment with mineralocorticoids&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects weighing less than 2 kg&#xD;
&#xD;
          -  Subjects less than 48 hours old&#xD;
&#xD;
          -  Presence of an acute infectious condition&#xD;
&#xD;
          -  Presence of mineralocorticoid treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresinha Leal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

